Recombinogenic activity of fluoxetine in Aspergillus nidulans

Drug and Chemical Toxicology

Volumn 32, Issue 4, 2009, Pages 338-343

  De Castro Prado, Juliana ^a   Da Silva Franco, Claudinia C ^a   De Sant'Anna, Juliane R ^a   Miyamoto, Claudia T ^a   De Castro Prado, Marialba A A ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Cancer patients; Fluoxetine; Second malignancy; Somatic recombination; Tumor promoters

Indexed keywords

FLUOXETINE; ANTIDEPRESSANT AGENT; FUNGAL PROTEIN;

ARTICLE; ASPERGILLUS NIDULANS; CONTROLLED STUDY; DRUG ACTIVITY; FUNGAL GENETICS; FUNGAL STRAIN; GENETIC RECOMBINATION; HETEROZYGOSITY; HOMOZYGOSITY; MITOTIC RECOMBINATION; NONHUMAN; TUMOR SUPPRESSOR GENE; CROSSING OVER; DIPLOIDY; DOSE RESPONSE; DRUG EFFECT; GENETICS; HETEROZYGOSITY LOSS; HETEROZYGOTE; HUMAN; METABOLISM; MICROBIOLOGICAL EXAMINATION; MUTATION; PHYSIOLOGY;

EMERICELLA NIDULANS;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ASPERGILLUS NIDULANS; CROSSING OVER, GENETIC; DIPLOIDY; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; FUNGAL PROTEINS; HETEROZYGOTE; HUMANS; LOSS OF HETEROZYGOSITY; MICROBIAL SENSITIVITY TESTS; MUTATION; RECOMBINATION, GENETIC;

EID: 74049126032     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.1080/01480540903155085     Document Type: Article

References (34)

1. Arnaudeau, C., Tenorio Miranda, E., Jensen, D., Helleday, T. (2000). Inhibition of DNA synthesis is a potent mechanism by which cytostatic drugs induce homologous recombination in mammalian cells. Mutat Res 461:221-228.
2. Becker, T. C. A., Castro-Prado, M. A. A. (2004). Parameiosis in Aspergillus nidulans in response to doxorubicin. Folia Microbiol 49:699-704.
3. Bergen, G. G., Morris, N. R. (1983). Kinetics of the nuclear division cycle of Aspergillus nidulans. J Bacteriol 156:155-160.
4. - mice and associates with mammary tumor susceptibility of the Balb/c strain. Cancer Res 64:5140-5147.
5. Bozkurt, G., Abay, E., Ates, I., Karabogaz, G., Ture, M., Savran, F. O., et al. (2004). Clastogenicity of selective serotonin-reuptake inhibitors. Mutat Res 558:137-144.
6. Cavenee, W. K., Scrable, H. J., James, C. D. (1991). Molecular genetics of human cancer predisposition and progression. Mutat Res 247:199-202.
7. Collins, K., Jacks, T., Pavletich, N. P. (1997). The cell cycle and cancer. Proc Natl Acad Sci U S A 94:2776-2778.
8. Fava, M., Kaji, J. (1994). Continuation and maintenance treatment of major depressive disorder. Psychiatr Ann 42:281-290.
9. Ferguson, J., Hill, H. (2003). The pharmacokinetics of fluoxetine in elderly volunteers ages 65-85. Eur Neuropsychopharmacol 13:181-181
10. Fernandes, A., Hoeck, E. V., Sandra, P., Lanc, F. M. (2008). Determination of fluoxetine in plasma by gas chromatography- mass spectrometry using stir bar sorptive extraction. Anal Chem Acta 614:201-207.
11. Fisch, M. (2004). Treatment of depression and cancer. J Natl Cancer Inst Monogr 32:105-111.
12. Frick, L. R., Palumbo, M. L., Zappia, M. P., Brocco, M. A., Cremaschi, G. A., Genaro, A. M. (2008). Inhibitory effect of fluoxetine on lymphoma growth through the modulation of antitumor T-cell response by serotonin-dependent and independent mechanisms. Biochem Pharmacol 75:1817-1826.
13. German, J. (1993). Bloom syndrome: a Mendelian prototype of somatic mutational disease. Medicine 72:393-406.
14. Helen, K. D. B., Subramanyam, S. (1991). Genotoxic evaluation of ara-c by multiple parameters. Mutat Res 263:185-196.
15. Jirkova, K., Mandys, V., Gispen, W. H., Bar, P. R. (2006). Cisplatininduced apoptosis in cultures of human Schwann cells. Neurosci Lett 392:22-26.
16. Lasko, D., Cavenee, W., Nordenskjold, M. (1991). Loss of constitutional heterozygosity in human cancer. Ann Rev Genet 25:281-314.
17. Luo, G., Santoro, I. M., McDaniel, L. D., Nishijima, I., Mills, M., Youssoufian, H., et al. (2000). Cancer predisposition caused by elevated mitotic recombination in Bloom mice. Nat Genet 26:424-429.
18. Maertens, O., Prenen, H., Debiec-Rychter, M., Wozniak, A., Sciot, R., Pauwels, P., et al. (2006). Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet 15:1015-1023.
19. Miyamoto, C. T., Sant'Anna, J. R., Franco, C. C. S., Castro-Prado, M. A. A. (2007). Genotoxicity (mitotic recombination) of the cancer chemotherapeutic agents, cisplatin and cytosine arabinoside, in Aspergillus nidulans. Food Chem Toxicol 45:1091-1095.
20. Offer, H., Erez, N., Zurer, I., Tang, X., Milyavsky, M., Goldfinger, N., et al. (2002). The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA. Carcinogenesis 23:1025-1032.
21. Portteus, A., Ahmad, N., Tobey, D., Leavery, P. L. (2006). The prevalence and use of antidepressant medication in pediatric cancer patients. J Child Adolesc Psychopharmacol 16:467-473.
22. Qian, F., Germino, G. G. (1997). Somatic genetics' 97 "Mistakes Happen": somatic mutation and disease. Am J Hum Genet 61:1000-1005.
23. Roper, J. A. (1952). Production of heterozygous diploids in filamentous fungi. Experientia 8:14-15.
24. Serafein, A., Holder, M. J., Grafton, G., Chamba, A., Drayson, M. T., Luong, Q. T., et al. (2003). Selective serotonin inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 101:3212-3219.
25. Serra, E., Rosenbaum, T., Nadal, M., Winner, U., Ars, E., Estivill, X., et al. (2001). Mitotic recombination effects homozygosity for NF1 germline mutations in neurofibromas. Nat Genet 28:294-296.
26. Shao, C., Deng, L., Henegariu, O., Liang, L., Raikwar, N., Sahota, A., Stambrook, P.J., Tischfield, J.A. (1999). Mitotic recombination produces the majority of recessive fibroblast variants in heterozygous mice. Proc. Natl. Acad. Sci. USA. 96: 9230-9235.
27. Sternbach, H. (2003). Are antidepressants carcinogenic? A review of preclinical and clinical studies. J. Clin. Psychiatry. 64: 1153-1162.
28. Stewart, D. R., Corless, C. L., Rubin, B. P., Heinrich, M. C., Messiaen, L. M., Kessler, L. J., et al. (2007). Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1. J Med Genet 44:e61.
29. Tanaka, K., Mansoor, A. M., Shigeta, C., Oguma, N., Kamada, N. (1992). Loss of heterozygosity at D3S2 locus of short arm of chromosome 3 in chronic myelogenous leukemia. Cancer Genet Cytogenet 61:42-45.
30. Uppin, M. S., Paul, T. R., Rajappa, S., Gayathri, K., Jacob, R., Uppin, S. G. (2007). Leukemia as a second malignancy. Ind J Pathol Microbiol 50:644-647.
31. van der Heijden, M. S., Yeo, C. J., Hruban, R. H., Kern, S. E. (2003). Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 63:2585-2588.
32. Vancura, R. W., Kepes, J. J., Newell, K. L., Ha, T. M., Arnold, P. M. (2006). Secondary intracranial neoplasms exhibiting features of astrocytoma and neuroblastoma in 2 children treated for acute lymphoblastic leukemia: report of 2 cases. Surg Neurol 65:490-494.
33. Yamada, T., Shinohara, K., Takeda, K., Kamed, N., Katsuki, K., Ariyoshi, K., et al. (1999). Second lung adenocarcinoma after combination chemotherapy in two patients with primary non-Hodgkin's lymphoma. Jpn J Clin Oncol 29:226-228.
34. Young, B. D., Debernardi, S., Lilington, D. M., Skoulakis, S., Chaplin, T., Foot, N. J., et al. (2006). A role for mitotic recombination in leukemogenesis. Adv Enzyme Regul 46:90-97.